FDA-Inspected Site

The Center for Reproductive Endocrinology

5 FDA inspections are on record for The Center for Reproductive Endocrinology in Dallas, United States.

Clean· No action indicated

Dallas, United States · Last updated July 10, 2026

Overview

  • 5 FDA inspections are on record.
  • 1 inspection produced a Form 483.
  • The most recent recorded inspection date is 2025-02-12.

At a glance

Inspections

5

Form 483s

1

EIRs

0

Last outcome

Clean

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
11 Feb 2025 – 12 Feb 2025BiologicsClean
1 Apr 2019 – 2 Apr 2019BiologicsClean
11 Apr 2016 – 13 Apr 2016BiologicsClean
10 Dec 2013 – 13 Dec 2013Biologics483View 483 →
26 Aug 2010Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

13 Dec 2013
21 CFR 1271.47(a)

Testing, screening, donor eligibility procedures

Cited by Young M Yoon, Elisa M Fleming

13 Dec 2013
21 CFR 1271.55(c)

Name and personal info on accompanying records

Cited by Young M Yoon, Elisa M Fleming

13 Dec 2013
21 CFR 1271.55(d)(1)(iii)

Documentation--determination, by whom, date

Cited by Young M Yoon, Elisa M Fleming

13 Dec 2013
21 CFR 1271.65(a)

Improper release prevention--storage, I.D.

Cited by Young M Yoon, Elisa M Fleming

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 1271.47(a)Cited across public-safe Form 483 observations1x
21 CFR 1271.55(c)Cited across public-safe Form 483 observations1x
21 CFR 1271.55(d)(1)(iii)Cited across public-safe Form 483 observations1x
21 CFR 1271.65(a)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind The Center for Reproductive Endocrinology's 1 Form 483

Verbatim observations and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat